Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Liquidia Co. stock logo
LQDA
Liquidia
$12.59
-2.8%
$14.64
$5.71
$16.99
$957.22M0.16944,597 shs583,314 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.09
+28.6%
$0.52
$0.05
$23.40
$453K1.31.39 million shs209,776 shs
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.53
-1.9%
$0.50
$0.26
$1.14
$18.58M1.5832,165 shs3,521 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.72
-3.6%
$3.89
$1.03
$5.07
$111.53M2.44183,481 shs13,274 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Liquidia Co. stock logo
LQDA
Liquidia
-1.75%-4.64%-22.59%+7.38%+90.44%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.00%-16.17%-85.44%-93.00%-99.44%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
+1.89%+8.54%+8.43%+3.85%-48.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
+3.21%-4.46%-8.75%+11.88%+73.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Liquidia Co. stock logo
LQDA
Liquidia
2.1065 of 5 stars
3.31.00.00.01.84.20.6
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.8006 of 5 stars
3.55.00.00.00.60.00.6
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
0.7736 of 5 stars
2.03.00.00.01.91.70.6
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.255 of 5 stars
3.33.00.00.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0066.80% Upside
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8831,983.33% Upside
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80616.98% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00115.05% Upside

Current Analyst Ratings

Latest SSKN, LQDA, STIM, and MOTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M54.73N/AN/A$0.73 per share17.25
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$320K1.41N/AN/A$1.74 per share0.05
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.56N/AN/A$0.37 per share1.43
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.56N/AN/A$1.18 per share3.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/7/2024 (Confirmed)

Latest SSKN, LQDA, STIM, and MOTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.33N/A+$0.33N/AN/AN/A
3/27/2024Q4 2023
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/A-$0.04-$0.04$0.03N/A$8.69 million
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
9935.06 million20.89 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.04 millionOptionable

SSKN, LQDA, STIM, and MOTS Headlines

SourceHeadline
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
globenewswire.com - April 23 at 4:30 PM
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.